The Impact of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Sleep Quality and Daytime Sleepiness in Migraine Patients: A Multicenter Study
Authors:
- Rita CagigalRCRita Cagigal
- Ângelo FonsecaÂFÂngelo Fonseca
- Bárbara MartinsBMBárbara Martins
- Catarina FernandesCFCatarina Fernandes
- Sandra PalmaSPSandra Palma
- Carolina GuerreiroCGCarolina Guerreiro
- Carla MorgadoCMCarla Morgado
- Diana ValenteDVDiana Valente
- Miguel MirandaMMMiguel Miranda
- Joana SilvaJSJoana Silva
- Miguel Saianda-DuarteMSMiguel Saianda-Duarte
- Sofia CasanovaSCSofia Casanova
Open Access
- 28 February 2026
- journal article
- Published by The Korean Headache Society in Headache and Pain Research
- Vol. 27 (1) , 43-51
Abstract
Purpose: This study aimed to determine whether patients with migraine experience improvements in self-reported sleep quality and daytime sleepiness after starting monoclonal antibody (mAb) therapy targeting the calcitonin gene-related peptide (CGRP) or its receptor, and to explore the association between treatment efficacy and improvements in sleep quality.Methods: This prospective, multicenter, observational, longitudinal study was conducted across 12 headache centers. Adults with episodic or chronic migraine who began anti-CGRP mAb therapy were assessed at baseline, 3 months, and 6 months. Sleep quality and daytime sleepiness were evaluated using the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT) and the Portuguese version of the Epworth Sleepiness Scale (ESS-PT), respectively. Results: Of 118 enrolled patients, 109 completed the study (86.4% female; mean age, 43.6 years). A significant improvement in sleep quality was observed, with median PSQI-PT scores decreasing from 9 at baseline to 6 at 6 months (p<0.001). Daytime sleepiness also improved, with median ESS-PT scores decreasing from 7 to 6 (p=0.04). Migraine frequency decreased significantly, from a median of 13 to 4 monthly migraine days (p<0.001). Greater migraine improvement was independently associated with greater PSQI-PT improvement (p<0.001), whereas changes in ESS-PT were not correlated with treatment efficacy.Conclusion: Anti-CGRP mAb therapy was associated with significant improvements in sleep quality, likely mediated through migraine relief. Changes in ESS-PT were not correlated with treatment efficacy, suggesting a possible interaction between migraine mechanisms and CGRP-mediated sleep–wake regulation. Future research should focus on clarifying the mechanisms underlying these associations.Keywords
This publication has 13 references indexed in Scilit:
- Effect of Atogepant on Sleep Quality and Sleep-Related Adverse Events in Adult Patients with Migraine: A Prospective Observational 12-Week StudyCNS Drugs, 2025
- Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: An Italian multicenter studySleep Medicine, 2024
- Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migrainePractical Neurology, 2023
- Subjective Sleep Quality and Sleep Architecture in Patients With MigraineNeurology, 2021
- Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysisCephalalgia, 2021
- Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targetingExpert Opinion on Therapeutic Targets, 2020
- Sleep Disorders and Migraine: Review of Literature and Potential Pathophysiology MechanismsHeadache: The Journal of Head and Face Pain, 2018
- Sleep and headaches: Relationships between migraine and non‐migraine headaches and sleep duration, sleep quality, chronotype, and obstructive sleep apnoea riskAustralian Journal of Psychology, 2017
- Validation of the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT)Psychiatry Research, 2017
- Calcitonin Gene-Related Peptide Neurons Mediate Sleep-Specific Circadian Output in DrosophilaCurrent Biology, 2014